NCT04724486

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

Effect of GnRH Agonist (Long Protocol) vs GnRH Antagonist (Flexible Protocol) on Oocyte Morphology During IVF/ICSI

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Damascus University · Academic / Other
• Sex: Female
• Age: 18 Years – 39 Years
• Healthy volunteers: Not accepted

Summary

Selection of developmentally competent oocytes enhances IVF efficiency. Usually, oocyte quality is determined based on its nuclear maturation and the presence of specific cytoplasmic and extracytoplasmic morphologic features. Gonadotropin-releasing hormone agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists) are used during controlled ovarian stimulation (COS) protocols in order to prevent premature luteinizing hormone (LH) surge and premature ovulation. However, GnRH receptors are also expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type of GnRH analogues used during COS could affect the oocyte morphology, especially with the limited and conflicted currently available data. Thus, we are conducting this prospective, non-randomised, open-label, clinical trial to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on oocyte morphology during IVF/ICSI.

Conditions

• In Vitro Fertilization
• Intracytoplasmic Sperm Injection
• Infertility

Interventions

Type	Name	Description
DRUG	Triptorelin acetate	0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
DRUG	Cetrorelix	0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
DRUG	recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin	Dosage adjustment according to the ovarian response.
DRUG	Human Chorionic Gonadotropin (hCG)	Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.

Timeline

• Start date: 2020-08-22
• Primary completion: 2022-03-15
• Completion: 2022-07-15
• First posted: 2021-01-26
• Last updated: 2023-10-24

Locations

1 site across 1 country: Syria